Revance Therapeu Stock Price, News & Analysis

Welcome to our dedicated page for Revance Therapeu news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeu stock.

The RVNC news page on Stock Titan provides an archive of announcements and transaction-related communications concerning Revance Therapeutics, Inc., a biotechnology company focused on aesthetic and therapeutic offerings. These news items document Revance’s role in the aesthetic injectables market, its product portfolio, and the corporate events that led to its acquisition by Crown Laboratories, Inc.

Readers can review press releases describing Crown’s commencement of a cash tender offer to acquire all outstanding shares of Revance, subsequent extensions of the tender offer, and an increase in the offer price that was unanimously approved by the Revance Board of Directors. Additional news items cover competing interest from Teoxane SA, reminders to Revance stockholders about tendering their shares, and joint announcements by Crown and Revance regarding the expiration of the tender offer and satisfaction of its conditions.

The archive also includes Crown’s announcements of the successful closing of the acquisition and completion of the second-step merger, in which Crown stated that Revance’s common stock will be delisted from the NASDAQ Global Select Market and deregistered. These releases provide context on how Revance, as the issuer of RVNC, transitioned from an independent publicly traded biotechnology company to a Crown-owned business within a larger skincare and aesthetics platform.

For investors and researchers, the RVNC news feed serves as a historical record of key milestones, including strategic reviews by the Revance Board, tender offer mechanics, and the ultimate outcome of the Crown transaction. Users interested in the evolution of Revance’s aesthetic and therapeutic portfolio, its partnerships with Teoxane SA, Viatris Inc., and Shanghai Fosun Pharmaceutical, and the terms of the acquisition can use this page to trace the sequence of public communications around the deal.